(Bloomberg) -- Bayer AG and Johnson & Johnson won a trial court ruling that upheld the validity of a patent on the blood-thinning drug Xarelto.
Mylan NV and Sigmapharm Laboratories failed to prove the patent shouldn’t have been issued, District Court Judge Lawrence Stengel said in a ruling posted on the court’s docket. The generic-drug companies, who are looking to sell low-cost versions of the drug, had conceded they infringed the patent, which expires in August 2024.
To contact the reporter on this story: Susan Decker in Washington at firstname.lastname@example.org
To contact the editors responsible for this story: Jon Morgan at email@example.com, Laurie Asséo
©2018 Bloomberg L.P.